Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
SIBN gained 9.5% through August 25 as Q2 revenue rose 15%, adjusted EBITDA increased 178%, losses beat consensus, the physician base grew 19%, and management raised 2026 guidance.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Narrowing Losses ⢠Persistent Deficit SIBN has strong liquidity and improving margins/cash flow, but persistent losses and a demanding valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Key support ⢠Near oversold Support Level: $18.00â$18.05 Resistance Level: $18.50â$18.70 SIBN is in a bearish last-month trend below its 21-day average, with $18.00â$18.05 support critical and a rebound requiring a break above $18.50â$18.70.
Sentiment & News
Key News Insights: ⢠Earnings Upgrades ⢠Target Upside ⢠Investor Engagement SI-Bone shows constructive momentum as rising earnings estimates and ~25% target upside are reinforced by management's healthcare conference participation.
AI Summary
SI-BONE is shifting toward an operating-leverage storyâsupported by 15% growth, expanding physician adoption, high gross margins, and initial positive operating cash flowâbut investors should wait for repeated cash-flow and EBITDA progress, as its premium valuation remains vulnerable if new physicians fail to ramp utilization and expenses do not scale.
Description
SI-BONE, Inc. is a medical device company that develops implantable products for musculoskeletal conditions affecting the sacropelvic anatomy in the United States and abroad. Its portfolio includes minimally invasive implants used in sacroiliac joint fusion and pelvic fracture repair, and it sells primarily through a direct sales force supplemented by distributors. The company was founded in 2008 and is based in Santa Clara, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 25 | Sep 1 | SIBN | SI-BONE, Inc. | SIBN gained 9.5% through August 25 as Q2 revenue rose 15%, adjusted EBITDA increased 178%, losses beat consensus, the physician base grew 19%, and management raised 2026 guidance. | Closed | -3.2% |